A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART

Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable vire...

Descripción completa

Detalles Bibliográficos
Autores: Gómez, Carmen E., Perdiguero, Beatriz, García Arriaza, Juan, Cepeda, Victoria, Sánchez-Sorzano, Carlos Óscar, Mothe, Beatriz, Jiménez, José Luis, Muñoz Fernández, María Ángeles, Gatell, J.M., López Bernaldo de Quirós, Juan Carlos, Brander, Christian, Garcia, Felipe, Esteban, Mariano
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:UVic-UCC
Repositorio:RiUVic. Repositori institucional de la UVic-UCC
OAI Identifier:oai:dspace.uvic.cat:10854/4418
Acceso en línea:http://hdl.handle.net/10854/4418
https://doi.org/10.1371/journal.pone.0141456
Access Level:acceso abierto
Palabra clave:Sida -- Tractament
VIH (Virus)
Descripción
Sumario:Trial Design Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1- specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses.

Similares en LA Referencia